Science

Britain partners with Oxford firm to assess coronavirus vaccine T cell responses

Reuters London | Updated on October 22, 2020 Published on October 22, 2020

T cell immunity is thought to be essential to protection against infection from the coronavirus; could provide longer-term immunity than antibodies

Britain on Thursday said it would partner with an Oxford-based firm to provide testing for the T cell response of coronavirus vaccine candidates to try to assess their immune responses.

T cell immunity is thought to be essential to protection against infection from the SARS-COV-2 coronavirus, and could provide longer-term immunity than antibodies.

The UK Vaccine Taskforce has chosen Oxford Immunotec to supply T cell testing for its assessment of different vaccine candidates.

Also read: Researchers explore how a virus can trigger diabetes

“It is important to be able to assess the different vaccines head-to-head and the T cell response is part of our portfolio of accredited assays that we are employing for cross comparisons,” Kate Bingham, chair of the UK Vaccines Taskforce, said in a statement.

Britain has signed supply deals for six different coronavirus vaccine candidates, including those being made by AstraZeneca and Pfizer and BioNTech, seen as among the frontrunners in the race for a vaccine.

Also read: China’s Covid-19 vaccine induces antibody response

Oxford Immunotec said its technology platform enabled the centralisation of fresh blood samples from different locations to measure the T cell response in a standardised way.

It said the platform, known as T-SPOT, was being used to identify the T cells made in response to the pathogen that causes tuberculosis.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on October 22, 2020
This article is closed for comments.
Please Email the Editor